Wnt/β-Catenin Inhibition by CWP232291 as a Novel Therapeutic Strategy in Ovarian Cancer

• Published in: Frontiers in oncology Vol. 12; p. 852260
• Main Authors: Wang, Wenyu, Cho, Untack, Yoo, Anna, Jung, Chae-Lim, Kim, Boyun, Kim, Heeyeon, Lee, Juwon, Jo, HyunA, Han, Youngjin, Song, Myoung-Hyun, Lee, Ja-Oh, Kim, Se Ik, Lee, Maria, Ku, Ja-Lok, Lee, Cheol, Song, Yong Sang
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 12-05-2022
• Subjects: CWP232291; Oncology; organoids; ovarian cancer; targeted therapy; Wnt/β-catenin; targeted therapy; ovarian cancer; Wnt/β-catenin; organoids; CWP232291
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2022.852260

The poor prognosis of ovarian cancer patients mainly results from a lack of early diagnosis approaches and a high rate of relapse. Only a very modest improvement has been made in ovarian cancer patient survival with traditional treatments. More targeted therapies precisely matching each patient are strongly needed. The aberrant activation of Wnt/β-catenin signaling pathway plays a fundamental role in cancer development and progression in various types of cancer including ovarian cancer. Recent insight into this pathway has revealed the potential of targeting Wnt/β-catenin in ovarian cancer treatment. This study aims to investigate the effect of CWP232291, a small molecular Wnt/β-catenin inhibitor on ovarian cancer progression. Various
,
and
models are established for CWP232291 testing. Results show that CWP232291 could significantly attenuate ovarian cancer growth through inhibition of β-catenin. Noticeably, CWP232291 could also s suppress the growth of cisplatin-resistant cell lines and ovarian cancer patient-derived organoids. Overall, this study has firstly demonstrated the anti-tumor effect of CWP232291 in ovarian cancer and proposed Wnt/β-catenin pathway inhibition as a novel therapeutic strategy against ovarian cancer.